12:00 AM
 | 
Nov 04, 2013
 |  BC Week In Review  |  Company News  |  Other News

Amarin endocrine/metabolic news

Amarin reduced headcount by 50% to reduce operating expenses following an Oct. 16 meeting of an FDA advisory committee, which voted against a label expansion for Amarin's Vascepa icosapent ethyl. At Dec. 31, 2012, Amarin had 111 employees....

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >